Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1537-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative efficacy of biological treatments for moderate‐to‐severe psoriasis: a network meta‐analysis adjusting for cross‐trial differences in reference arm response

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 2, 2015-02 ,pp. : 504-512

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

By  

Psychotherapy and Psychosomatics, Vol. 86, Iss. 5, 2017-09 ,pp. : 260-267

Karger

Access to resources Recommend Favorite

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e105-e107

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite